An open label, multicentre, Phase II study in metastatic TNBC, ER+/HER2- PTEN (phosphatase and tensin homolog) low or ER+/HER2- PTEN intact breast cancer patients treated with CFI-400945 was initiated, showing that the drug was well tolerated with a moderate incidence of uncomplicated neutropenia [87] (Table 3). The gene discussed is PTEN; the disease is breast cancer.